NasdaqGS - Nasdaq Real Time Price ? USD Edgewise Therapeutics, Inc. (EWTX) Follow Compare 35.57 +0.06 (+0.17%) At close: October 18 at 4:00 PM EDT 35.51 -0.06 (-0.17%) After hours: October 18 at 5:30 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against the other hot stocks. While the market is seeing significant positives after the Fed rate cut, there have been some pressures. For example, […] Insider Monkey ? 13 days ago EWTX +0.17% Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society BOULDER, Colo., October 01, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual Congress of the World Muscle Society (WMS) with an industry-sponsored symposium and the presentation of seven scientific posters. These presentations will highlight the effects of sevasemten in individuals with Becker based on findings from the DUNE and ARCH clinical trials, as well as provide perspec Business Wire ? 19 days ago EWTX +0.17% Novo sinks on obesity drug results; Sanofi reveals anticipated MS data A pill Novo acquired?produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining?it found in a recent study and a heart drug developer’s shares surged. BioPharma Dive ? 30 days ago EWTX +0.17% NVO SNY Company News for Sep 20, 2024 Companies In The News Are: PGNY, EWTX, FDS, SCS. Zacks ? 30 days ago PGNY EWTX +0.17% SCS Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials In the Phase I trial, EDG-7500 was found to be well-tolerated without any significant changes in vital signs. Clinical Trials Arena ? 30 days ago EWTX +0.17% How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients. Investor's Business Daily ? last month EWTX +0.17% CYTK Why Edgewise Therapeutics Stock Is Up 50% on Thursday One of the biopharma company's heart drugs performs as well as initially hoped. Motley Fool ? last month EWTX +0.17% EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients. Zacks ? last month EWTX +0.17% Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) BOULDER, Colo., September 19, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM. Business Wire ? last month EWTX +0.17% Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time BOULDER, Colo., September 17, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM on Thursday, September 19, 2024, at 8:30 am ET. The team will be joined by CIRRUS-HCM investigator, Anjali T. Owens, M.D. Business Wire ? last month EWTX +0.17% Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... Simply Wall St. ? 2 months ago EWTX +0.17% Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights BOULDER, Colo., August 08, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second quarter of 2024 and recent business highlights. Business Wire ? 2 months ago EWTX +0.17% 7 Small-Cap Stocks to Buy for Large-Scale Gains Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential. Basically, it comes down to a mathematical concept. Because both the price and expectations for such diminutive enterprises are deflated, when they generate positive momentum, the reaction could be quite intense. That’s why speculators continue to pour money into small-cap stocks. That said, prospective participants should be aware of the dangers of this ecosystem. While InvestorPlace ? 2 months ago MUX LPG DNUT ‘Don’t Be Scared of Heights’: J.P. Morgan Suggests 2 Stocks to Buy There’s no denying we’re in a bull market. Over the past 18 months, with only a few blips, the markets have been trending upwards – and usually at a fast clip. Such rallies inevitably raise a few questions, particularly: how long will it last? A recent note from J.P. Morgan explains why current conditions may indicate that we may not be anywhere near the end of this rally. Writing for the investment bank, global investment strategist Sarah Stillpass notes, “If this bull market merely matches the TipRanks ? 2 months ago EWTX +0.17% TYL Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out. Zacks ? 3 months ago EWTX +0.17% Three Surprising Names That Could Be On Biogen's Buyout Shortlist Biogen stock has mostly trended sideways this year, but that could soon change with up to $10 billion in dry powder, an analyst said Tuesday. Investor's Business Daily ? 3 months ago BIIB PHVS EWTX +0.17% Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results Performance Analysis and Future Clinical Prospects GuruFocus.com ? 5 months ago EWTX +0.17% Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 BOULDER, Colo., May 10, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET. Business Wire ? 5 months ago EWTX +0.17% Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights BOULDER, Colo., May 09, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2024 and recent business highlights. Business Wire ? 5 months ago EWTX +0.17% Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors BOULDER, Colo., May 07, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. Business Wire ? 5 months ago EWTX +0.17% Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return EWTX S&P 500 YTD +225.14% +22.95% 1-Year +393.34% +34.10% 3-Year +100.51% +31.16%
